NeoGenomics sees FY25 revenue $735M-$745M, consensus $727.9M

Sees FY25 adjusted EBITDA $55M-$58M. “We enter 2025 with our patient-centric strategy in place, focusing on product innovation, further optimization and expansion of our commercial organization, and enhancing operational efficiencies,” said Chris Smith, chief executive officer of NeoGenomics (NEO). “Building on the strong momentum of double-digit revenue growth and margin expansion we have delivered over the last few years, we are updating our Long-Range Plan and now expect revenue growth of 12-13% annually, while expanding our leadership position in oncology testing.”